A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
A new HIV prevention drug by Gilead, twice-yearly shot lenacapavir, was found highly effective in a study. Despite excluding many Latin American countries, Gilead plans to offer generic versions in 120 high-risk countries.